10 August 2021 in Journal of Cellular and Molecular Medicine
Colorectal cancer (CRC) is the third most malignant tumour worldwide, with high mortality and recurrence. Chemoresistance is one of the main factors leading to metastasis and poor prognosis in advanced CRC patients. By analysing the Gene Expression Omnibus data set, we found higher hexokinase 2 (HK2) expression levels in patients with metastatic CRC than in those with primary CRC. Moreover, we observed higher enrichment in oxaliplatin resistance‐related gene sets in metastatic CRC than in primary CRC. However, the underlying relationship has not yet been elucidated. In our study, HK2 expression was significantly elevated in CRC patients. Gene set enrichment analysis (GSEA) revealed multi‐drug resistance and epithelial‐mesenchymal transition (EMT) pathways related to high HK2 expression. Our results showed that knockdown of HK2 significantly inhibited vimentin and Twist1 expression and promoted TJP1 and E‐cadherin expression in CRC cells. Additionally, transcriptional and enzymatic inhibition of HK2 by 3‐bromopyruvate (3‐bp) impaired oxaliplatin resistance in vitro and in vivo. Mechanistically, HK2 interacts with and stabilized Twist1 by preventing its ubiquitin‐mediated degradation, which is related to oxaliplatin resistance, in CRC cells. Overexpression of Twist1 reduced the apoptosis rate by HK2 knockdown in CRC cells. Collectively, we discovered that HK2 is a crucial regulator that mediates oxaliplatin resistance through Twist1. These findings identify HK2 and Twist1 as promising drug targets for CRC chemoresistance.
15 November 2021 in Oncogene
4 August 2020 in Oncogene
26 June 2023 in British Journal of Haematology
14 November 2025 in Research Square
As a highly vascularized tumor, the recurrence and metastasis of bladder cancer (BLCA) are closely related to tumor angiogenesis. We previously identified that TJP1 as an important target in the regulation of BLCA vasculogenesis regulation. However, the molecular mechanisms and related signaling pathways still require characterization. In this study, we reported that the overexpression of deubiquitinase-USP8 obviously increased the expression and stability of TJP1, thereby promoting BLCA neovascularization. Mechanistically, USP8 competitively bound to TJP1, preventing the ubiquitin-mediated degradation of TJP1 by the E3 ligase TRIM21 through the TJP1 K695 site. Furthermore, LYN kinase-mediated phosphorylation of TJP1 played a key role in the ubiquitination regulation by USP8 and TRIM21, improving TJP1 stability. In addition, phosphorylated TJP1 significantly increased binding to TWIST1, thereby increasing the nuclear localization of TJP1/TWIST1 complex and thus promoting transcriptional activation of CCL2, ultimately leading to BLCA vascular remodeling. Moreover, the LYN inhibitor combined with the USP8 inhibitor obviously decreased the lung metastasis of BLCA cells in murine tumor models. In conclusion, our findings shed new light on the function of TJP1 function in BLCA and provide favorable evidence that TJP1 and its upstream molecules might be new targets for BLCA treatment.